{"doi":"10.3390/jcm12185771","title":"Swiss Pilot Low-Dose CT Lung Cancer Screening Study: First Baseline Screening Results","abstract":"<jats:p>This pilot study conducted in Switzerland aims to assess the implementation, execution, and performance of low-dose CT lung cancer screening (LDCT-LCS). With lung cancer being the leading cause of cancer-related deaths in Switzerland, the study seeks to explore the potential impact of screening on reducing mortality rates. However, initiating a lung cancer screening program poses challenges and depends on country-specific factors. This prospective study, initiated in October 2018, enrolled participants meeting the National Lung Cancer Study criteria or a lung cancer risk above 1.5% according to the PLCOm2012 lung cancer risk-model. LDCT scans were assessed using Lung-RADS. Enrollment and follow-up are ongoing. To date, we included 112 participants, with a median age of 62 years (IQR 57–67); 42% were female. The median number of packs smoked each year was 45 (IQR 38–57), and 24% had stopped smoking before enrollment. The mean PLCOm2012 was 3.7% (±2.5%). We diagnosed lung cancer in 3.6% of participants (95%, CI:1.0–12.1%), with various stages, all treated with curative intent. The recall rate for intermediate results (Lung-RADS 3,4a) was 15%. LDCT-LCS in Switzerland, using modified inclusion criteria, is feasible. Further analysis will inform the potential implementation of a comprehensive lung cancer screening program in Switzerland.</jats:p>","journal":"Journal of Clinical Medicine","year":2023,"id":592175,"datarank":0.4719702407987232,"base_score":2.302585092994046,"endowment":2.302585092994046,"self_citation_contribution":0.3453877639491069,"citation_network_contribution":0.1265824768496163,"self_endowment_contribution":0.3453877639491069,"citer_contribution":0.1265824768496163,"corpus_percentile":null,"corpus_rank":null,"citation_count":9,"citer_count":7,"citers_with_citation_signal":3,"citers_with_endowment":3,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1515283,"name":"Harry Etienne","orcid":null,"position":1,"is_corresponding":false},{"id":1515284,"name":"Caroline Zellweger","orcid":null,"position":2,"is_corresponding":false},{"id":1288397,"name":"Alessandra Matter","orcid":null,"position":3,"is_corresponding":false},{"id":684459,"name":"Miriam Patella","orcid":"0000-0002-7622-9472","position":4,"is_corresponding":false},{"id":1338777,"name":"Thomas Frauenfelder","orcid":"0000-0002-3295-6619","position":5,"is_corresponding":false},{"id":514886,"name":"Isabelle Opitz","orcid":"0000-0001-5900-9040","position":6,"is_corresponding":false},{"id":1515282,"name":"Lisa Jungblut","orcid":"0000-0003-2078-4730","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Swiss Pilot Low-Dose CT Lung Cancer Screening Study: First Baseline Screening Results","abstract":"<jats:p>This pilot study conducted in Switzerland aims to assess the implementation, execution, and performance of low-dose CT lung cancer screening (LDCT-LCS). With lung cancer being the leading cause of cancer-related deaths in Switzerland, the study seeks to explore the potential impact of screening on reducing mortality rates. However, initiating a lung cancer screening program poses challenges and depends on country-specific factors. This prospective study, initiated in October 2018, enrolled participants meeting the National Lung Cancer Study criteria or a lung cancer risk above 1.5% according to the PLCOm2012 lung cancer risk-model. LDCT scans were assessed using Lung-RADS. Enrollment and follow-up are ongoing. To date, we included 112 participants, with a median age of 62 years (IQR 57–67); 42% were female. The median number of packs smoked each year was 45 (IQR 38–57), and 24% had stopped smoking before enrollment. The mean PLCOm2012 was 3.7% (±2.5%). We diagnosed lung cancer in 3.6% of participants (95%, CI:1.0–12.1%), with various stages, all treated with curative intent. The recall rate for intermediate results (Lung-RADS 3,4a) was 15%. LDCT-LCS in Switzerland, using modified inclusion criteria, is feasible. Further analysis will inform the potential implementation of a comprehensive lung cancer screening program in Switzerland.</jats:p>","is_dataset_classified":null,"base_score":2.302585092994046,"endowment":2.302585092994046,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"37762713","pmcid":"PMC10531743","openalex_id":"https://openalex.org/W4386457524","authors":[],"funders":[],"total_grants":0,"fwci":1.4996,"citation_percentile":0.833763,"influential_citations":0,"citation_trend":[{"year":2024,"count":2},{"year":2025,"count":1},{"year":2026,"count":6}],"oa_status":"gold","license":"cc-by","oa_locations":[{"url":"https://www.mdpi.com/2077-0383/12/18/5771/pdf?version=1693897170","host_type":"journal"},{"url":"https://www.mdpi.com/2077-0383/12/18/5771/pdf?version=1693897170","host_type":"publisher"},{"url":"https://www.mdpi.com/2077-0383/12/18/5771/pdf","host_type":"publisher"},{"url":"https://doi.org/10.3390/jcm12185771","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/37762713","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/10531743","host_type":"repository"},{"url":"https://dx.doi.org/10.3390/jcm12185771","host_type":"repository"},{"url":"https://doi.org/10.5167/uzh-238411","host_type":"repository"},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10531743/pdf/jcm-12-05771.pdf","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC10531743","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC10531743?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Lung Cancer Diagnosis and Treatment","Lung Cancer Treatments and Mutations","Chronic Obstructive Pulmonary Disease (COPD) Research"],"mesh_terms":[],"keywords":["Medicine","Lung cancer","Lung cancer screening","Cancer","Lung","Prospective cohort study","Internal medicine","National Lung Screening Trial","Screening","Diagnosis","Non-small cell lung cancer (NSCLC)","computed tomography"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-26T12:31:44.778273Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}